EyePoint's DURAVYU misses primary endpoint in Phase 3 LUCIA trial for wet AMD

• EyePoint announced topline results showing DURAVYU failed the main goal in its second pivotal wet age-related macular degeneration trial, LUCIA.
• Vision improved, but DURAVYU did not demonstrate non-inferiority to aflibercept; the first pivotal trial, LUGANO, also missed its primary endpoint.
• LUCIA showed reduced treatment burden, strong anatomical control and a continued favorable safety profile with repeat dosing.
• Additional analyses of both trials will guide next steps for DURAVYU in wet AMD.
• The diabetic macular edema program remains on track, with pivotal COMO and CAPRI trial results expected in the fourth quarter of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EyePoint Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-424644), on October 19, 2026, and is solely responsible for the information contained therein.